The following is a summary of updated recommendations and new data on COVID-19 vaccination in MS patients. (See also DMTs and vaccine response in MS: the evidence to date, NeuroSens, July 27, 2021.) Read More
Latest News
High-efficacy DMTs – Early treatment and novel endpoints
November 22, 2021ECTRIMS SPECIAL REPORT
The recently concluded European Committee on Treatment and Research in MS (ECTRIMS) annual meeting presented a number of new approaches for evaluating the efficacy of high-efficacy disease-modifying therapies. Read More
ECTRIMS special report: Update on anti-CD20 agents
November 9, 2021The European Committee for Treatment and Research in MS (ECTRIMS) annual meeting presented new data that helped to clarify the mode of action of anti-CD20 agents and address some safety issues that have arisen during the COVID-19 pandemic. Read More
CLINICAL CASES IN MS – CASE 1: Neurological symptoms after COVID-19 vaccination
November 2, 2021Watch Dr. Daniel Selchen as he shares his thoughts about this case.
Linda H., 48, is a partner at an accountancy firm, married with no children. She presents with paresthesiae following vaccination for COVID-19. She has no history of medical or neurological conditions and no pertinent family history. Read More